Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

1.76
-0.1300-6.88%
Post-market: 1.70-0.0600-3.41%17:27 EDT
Volume:8.13M
Turnover:14.67M
Market Cap:377.36M
PE:-1.91
High:2.01
Open:2.00
Low:1.70
Close:1.89
52wk High:2.74
52wk Low:0.3546
Shares:214.41M
Float Shares:132.00M
Volume Ratio:0.67
T/O Rate:6.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9194
EPS(LYR):-1.4333
ROE:-120.08%
ROA:-53.25%
PB:8.82
PE(LYR):-1.23

Loading ...

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 07

Cantor Fitzgerald Initiates Invivyd at Overweight With $10 Price Target

MT Newswires Live
·
Oct 06

Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug

Dow Jones
·
Oct 06

Invivyd Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Oct 06

BRIEF-Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311

Reuters
·
Oct 06

Invivyd Receives FDA Clearance to Advance Pivotal Clinical Trials for VYD2311, a Monoclonal Antibody COVID-19 Vaccine Alternative

Reuters
·
Oct 06

Invivyd Announces U.S. Ind Clearance and Alignment With U.S. FDA on Pivotal Clinical Program for Vyd2311, a Vaccine-Alternative Antibody to Prevent Covid

THOMSON REUTERS
·
Oct 06

Invivyd Inc: Declaration and Liberty Clinical Trials Expected to Begin Around Year-End 2025; Top-Line Data Anticipated Mid-2026

THOMSON REUTERS
·
Oct 06

Invivyd Files $350 Million Mixed Shelf Offering

MT Newswires Live
·
Oct 03

Invivyd files $350M mixed securities shelf

TIPRANKS
·
Oct 03

Invivyd Inc : Files for Mixed Shelf Offering of up to $350 Mln - SEC Filing

THOMSON REUTERS
·
Oct 03

Invivyd Appoints Paul B. Bolno, M.D. To Its Board Of Directors

Reuters
·
Sep 25

Invivyd Inc. Files Initial Beneficial Ownership Statement for Director Paul Bolno

Reuters
·
Sep 25

Press Release: Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Dow Jones
·
Sep 25

Press Release: Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

Dow Jones
·
Sep 17

Invivyd Inc. Announces New Clinical Study to Evaluate Monoclonal Antibody Therapy for Long COVID at RECOVER-TLC Workshop

Reuters
·
Sep 04

Steven Cohen Reports 8.0% Passive Stake in Invivyd Inc as of August 26 - SEC Filing

THOMSON REUTERS
·
Aug 28

Invivyd Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 27

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 25

Invivyd Inc. Closes $57.5 Million Public Offering, Fully Exercises Underwriter's Option for Additional Shares

Reuters
·
Aug 23